Dare Bioscience (NASDAQ: DARE) — Perfil da empresa, notícias e dados financeiros
Dare Bioscience focuses on women's reproductive health, advancing innovative products across various life stages.
Dare Bioscience
Dare Bioscience (NASDAQ:DARE) is a biopharmaceutical company focused on women's reproductive health. By advancing innovative products for women, Dare aims to improve their well-being across various life stages, addressing needs in contraception, vaginal health, fertility, and sexual health. The company's diverse portfolio includes clinical-stage drug projects designed to provide better treatment options and enhance quality of life. Through research and partnerships, Dare Bioscience is committed to delivering groundbreaking therapies that can fulfill unmet medical needs for women around the globe, thereby achieving its mission to revolutionize women's healthcare.
Resumo
Operações
Produtos e/ou serviços de Dare Bioscience
- Ovaprene, a non-hormonal, monthly contraceptive designed to provide a mixture of spermicides within a vaginal ring.
- Sildenafil Cream, 3.6%, a novel topical treatment aimed at enhancing female sexual arousal by increasing blood flow.
- XACIATO (Clindamycin Phosphate Vaginal Gel, 2%), developed for the treatment of bacterial vaginosis in female patients.
- DARE-HRT1, a bioidentical combination of estradiol and progesterone in a single, intravaginal ring for hormone therapy.
- DARE-FRT1, targeting the development of a formulation for ovarian hormone replacement therapy in women suffering from premature ovarian insufficiency.
- DARE-RH1, an investigational nasal spray for the treatment of reproductive health issues, leveraging a novel delivery system.
equipe executiva do Dare Bioscience
- Sabrina Martucci JohnsonCEO, President, Principal Financial Officer, Secretary & Director
- MarDee J. Haring-LaytonChief Accounting Officer
- Mark WaltersVice President of Operations
- David FriendChief Scientific Officer
Principais indicadores financeiros
Resultados divulgados pela Dare Bioscience, em USD.
- Cap. de mercado
- 13,4 mi
- Receita (TTM)
- 1,4 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.7
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 1 mi | -13,6 mi | -13,4 mi | |
| 9,8 mil | -23,5 mi | -4,1 mi | |
| 2,8 mi | -30,9 mi | -30,2 mi | |
| 10 mi | -31,4 mi | 406,8 mi |